ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 52 filers reported holding ALIGOS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,494 | -48.7% | 2,000 | -33.3% | 0.00% | – |
| Q2 2023 | $2,913 | -97.5% | 3,000 | -97.7% | 0.00% | – |
| Q1 2023 | $116,001 | +5071.7% | 132,724 | +5540.6% | 0.00% | – |
| Q4 2022 | $2,243 | -79.6% | 2,353 | -77.1% | 0.00% | – |
| Q3 2022 | $11,000 | -82.8% | 10,282 | -80.5% | 0.00% | – |
| Q2 2022 | $64,000 | -62.6% | 52,613 | -34.3% | 0.00% | – |
| Q1 2022 | $171,000 | -72.1% | 80,110 | +55.0% | 0.00% | – |
| Q4 2021 | $613,000 | -91.6% | 51,670 | -89.0% | 0.00% | -100.0% |
| Q3 2021 | $7,280,000 | +2146.9% | 469,404 | +2859.9% | 0.00% | – |
| Q2 2021 | $324,000 | -58.5% | 15,859 | -53.8% | 0.00% | – |
| Q1 2021 | $780,000 | +36.8% | 34,315 | +66.6% | 0.00% | – |
| Q4 2020 | $570,000 | – | 20,593 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,320,381 | $47,301,000 | 15.67% |
| Pivotal bioVenture Partners Investment Advisor LLC | 876,548 | $17,873,000 | 7.04% |
| Vivo Capital, LLC | 3,547,030 | $72,306,000 | 3.13% |
| Novo Holdings A/S | 2,614,563 | $53,311,000 | 2.36% |
| ACUTA CAPITAL PARTNERS, LLC | 214,254 | $4,368,000 | 1.75% |
| Boxer Capital, LLC | 1,526,048 | $31,108,000 | 1.10% |
| VR Adviser, LLC | 408,377 | $8,325,000 | 1.01% |
| Cormorant Asset Management, LP | 905,467 | $18,458,000 | 0.63% |
| HHLR ADVISORS, LTD. | 2,165,064 | $44,135,000 | 0.45% |
| Logos Global Management LP | 212,785 | $4,339,000 | 0.36% |